Shots:

• Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to be initiated in mid-May with its preliminary immunogenicity and safety results in July
• The study will be the third confirmed global COVID-19 vaccine trial and the first in Australia (at Melbourne and Brisbane clinical sites). Nucleus will assist Novavax to undertake P-I study and fast track NVX-CoV2373 for its early development
• Nucleus has applied its highest level of transmission-based precautions within its clinical units including its clinical staff- which makes it an ideal partner for Novavax to rapidly develop a vaccine for COVID-19

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Nucleus

Related News: Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020